Fulgenzi Alessandro, De Giuseppe Rachele, Bamonti Fabrizia, Ferrero Maria Elena
Department of Biomedical Sciences for Health, University of Milan, Via L. Mangiagalli 31, 20133 Milan, Italy.
Department of Biomedical, Surgical and Dental Sciences, University of Milan and Haematology-Oncology and BMT Unit, IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via F. Sforza 33, 20122 Milan, Italy.
Biomed Res Int. 2014;2014:281510. doi: 10.1155/2014/281510. Epub 2014 Jul 10.
This prospective pilot study aimed at evaluating the effects of therapy with antioxidant compounds (Cellfood, and other antioxidants) on patients affected by neurodegenerative diseases (ND), who displayed toxic metal burden and were subjected to chelation treatment with the chelating agent calcium disodium ethylenediaminetetraacetic acid (CaNa2EDTA or EDTA).
Two groups of subjects were studied: (a) 39 patients affected by ND and (b) 11 subjects unaffected by ND (controls). The following blood parameters were analyzed before and after three months' treatment with chelation+Cellfood or chelation+other antioxidants: oxidative status (reactive oxygen species, ROS; total antioxidant capacity, TAC; oxidized LDL, oxLDL; glutathione), homocysteine, vitamin B12, and folate.
After 3-months' chelation+Cellfood administration oxLDL decreased, ROS levels were significantly lower, and TAC and glutathione levels were significantly higher than after chelation+other antioxidants treatment, both in ND patients and in controls. Moreover, homocysteine metabolism had also improved in both groups.
Chelation+Cellfood treatment was more efficient than chelation+other antioxidants improving oxidative status and homocysteine metabolism significantly in ND patients and controls. Although limited to a small number of cases, this study showed how helpful antioxidant treatment with Cellfood was in improving the subjects' metabolic conditions.
本前瞻性试点研究旨在评估抗氧化化合物(细胞食物及其他抗氧化剂)对患有神经退行性疾病(ND)、体内有毒金属负荷且接受螯合剂乙二胺四乙酸二钠钙(CaNa2EDTA或EDTA)螯合治疗的患者的治疗效果。
研究了两组受试者:(a)39例患有神经退行性疾病的患者和(b)11例未患神经退行性疾病的受试者(对照组)。在用螯合 + 细胞食物或螯合 + 其他抗氧化剂治疗三个月前后,分析了以下血液参数:氧化状态(活性氧,ROS;总抗氧化能力,TAC;氧化型低密度脂蛋白,oxLDL;谷胱甘肽)、同型半胱氨酸、维生素B12和叶酸。
在ND患者和对照组中,给予螯合 + 细胞食物治疗3个月后,oxLDL降低,ROS水平显著降低,TAC和谷胱甘肽水平显著高于螯合 + 其他抗氧化剂治疗后。此外,两组的同型半胱氨酸代谢也有所改善。
螯合 + 细胞食物治疗比螯合 + 其他抗氧化剂治疗更有效,能显著改善ND患者和对照组的氧化状态和同型半胱氨酸代谢。尽管该研究仅限于少数病例,但显示了细胞食物抗氧化治疗对改善受试者代谢状况的帮助。